Stephen A. Harrison
Impact in
- Hepatology top 0.05%
- Liver Disease and Transplantation
- Liver Diseases and Immunity
- Hepatitis C virus research
- Epidemiology top 0.01%
- Liver Disease Diagnosis and Treatment
Papers in
- Epidemiology 261
- Liver Disease Diagnosis and Treatment 250
- Hepatology 97
- Hepatitis C virus research 39
- Liver Diseases and Immunity 31
- Liver Disease and Transplantation 25
- Hepatocellular Carcinoma Treatment and Prognosis 23
- Co-authors
- Arun J. Sanyal (67 shared papers)Kenneth Cusi (23 shared papers)Zobair M. Younossi (46 shared papers)Elizabeth M. Brunt (9 shared papers)Dawn M. Torres (23 shared papers)Mary E. Rinella (26 shared papers)Michael Charlton (7 shared papers)Naga Chalasani (8 shared papers)
- Journals
- Journal of Hepatology (74 papers)Hepatology (38 papers)Gastroenterology (25 papers)Clinical Gastroenterology and Hepatology (22 papers)Alimentary Pharmacology & Therapeutics (14 papers)
- Partner nations
- United StatesUnited KingdomFrance
In The Last Decade
Stephen A. Harrison
393 papers receiving 32.4k citations
Stephen A. Harrison's Hit Papers
Peers
Comparison fields: 5 of 185
- Hepatology 7.5k
- Epidemiology 23.1k
- Endocrinology, Diabetes and Metabolism 8.8k
- Pathology and Forensic Medicine 2.4k
- Cell Biology 2.3k
Countries citing papers authored by Stephen A. Harrison
This map shows the geographic impact of Stephen A. Harrison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen A. Harrison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen A. Harrison more than expected).
Fields of papers citing papers by Stephen A. Harrison
This network shows the impact of papers produced by Stephen A. Harrison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen A. Harrison. The network helps show where Stephen A. Harrison may publish in the future.
Co-authors
The 25 scholars most cited alongside Stephen A. Harrison, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 411 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases Hit paper breakdown → | 2017 | 5284 |
| 2 | Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study Hit paper breakdown → | 2010 | 1714 |
| 3 | A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis Hit paper breakdown → | 2006 | 1413 |
| 4 | A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis Hit paper breakdown → | 2020 | 1324 |
| 5 | Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma: A Weighty Connection Hit paper breakdown → | 2010 | 1091 |
| 6 | Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease Hit paper breakdown → | 2008 | 662 |
| 7 | Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial Hit paper breakdown → | 2019 | 562 |
| 8 | Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis Hit paper breakdown → | 2003 | 546 |
| 9 | Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial Hit paper breakdown → | 2018 | 431 |
| 10 | Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease Hit paper breakdown → | 2021 | 380 |
| 11 | 2003 | 370 | |
| 12 | 2011 | 360 | |
| 13 | 2008 | 355 | |
| 14 | NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial Hit paper breakdown → | 2018 | 353 |
| 15 | Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH Hit paper breakdown → | 2023 | 314 |
| 16 | 2008 | 289 | |
| 17 | Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study Hit paper breakdown → | 2020 | 285 |
| 18 | Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials Hit paper breakdown → | 2020 | 283 |
| 19 | From NAFLD to MAFLD: Implications of a Premature Change in Terminology Hit paper breakdown → | 2020 | 280 |
| 20 | Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial Hit paper breakdown → | 2021 | 271 |
About Stephen A. Harrison
Stephen A. Harrison is a scholar working on Epidemiology, Hepatology, Endocrinology, Diabetes and Metabolism, Plant Science and Molecular Biology, having authored 411 papers that have together received 33.1k indexed citations. Recurring topics across this work include Liver Disease Diagnosis and Treatment (250 papers), Diet, Metabolism, and Disease (56 papers), Hepatitis C virus research (39 papers), Wheat and Barley Genetics and Pathology (34 papers), Liver Diseases and Immunity (31 papers), Liver Disease and Transplantation (25 papers), Hepatocellular Carcinoma Treatment and Prognosis (23 papers) and Alcohol Consumption and Health Effects (17 papers). The work is most often cited by research in Hepatology (7.5k citations), Epidemiology (23.1k citations), Endocrinology, Diabetes and Metabolism (8.8k citations), Pathology and Forensic Medicine (2.4k citations) and Cell Biology (2.3k citations). Stephen A. Harrison has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include Arun J. Sanyal, Kenneth Cusi, Zobair M. Younossi, Elizabeth M. Brunt, Dawn M. Torres, Mary E. Rinella, Michael Charlton, Naga Chalasani, Joel E. Lavine and Brent A. Neuschwander‐Tetri. Their work appears in journals such as Journal of Hepatology, Hepatology, Gastroenterology, Clinical Gastroenterology and Hepatology and Alimentary Pharmacology & Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.